title: Long-term treatment with acarbose for the treatment of reactive hypoglycemia.
abstract: OBJECTIVE
  Acarbose, a potent alpha-glucosidase inhibitor, provides a new concept for the treatment of metabolic disorders, and particularly diabetes mellitus. It reduces the postprandial blood glucose increment and insulin response. For this reason the drug has been successfully used not only in the treatment of type 1 and type 2 diabetes, but also in the management of reactive hypoglycemia and dumping syndrome. The primary aim of the present study is to evaluate the long-term effect of acarbose in reducing hypoglycemic symptoms and influencing laboratory measurements in patients with the diagnosis of reactive hypoglycemia.
  
  
  METHODS
  21 non-obese (BMI < 27 kg/m2) patients (6 males, 15 females) complaining of postprandial symptoms suggesting hypoglycemia and who showed blood glucose values of < 54 mg/dl on one or more occasions during a 5 h oral glucose tolerance test (OGTT) were selected.
  
  
  RESULTS
  Before treatment, ingestion of glucose decreased plasma glucose levels at the 3rd and 4th hours, the lowest levels being 39 mg/dl and 45 mg/dl respectively. Eighteen patients had hypoglycemic symptoms during OGTT. Following 3 months of acarbose treatment, the lowest plasma glucose levels at the 3rd and 4th hours increased to 67 mg/dI and 75 mg/dI respectively. Plasma insulin and c-peptide levels were reduced between the 1st and 5th hours, but only the 1st and 2nd hour decrements were statistically significant. The area under the curve (AUC) between 0-300 minutes for insulin was not significant. Plasma glucose levels were significantly increased during the last 3 hours. The AUC for glucose was not significantly changed. Frequency of hypoglycemic attacks was reduced from 4 times a week to 1. C-peptide levels in 24-hour urine collection did not change significantly: 45 micrograms/I and 56 micrograms/I respectively before and after treatment.
  
  
  CONCLUSIONS
  These results confirm that acarbose may be of value in preventing reactive hypoglycemia by reducing the early hyperglycemic stimulus to insulin secretion, and in the treatment of reactive hypoglycemia.
authors.affiliation: Ege University Endocrinology Department, Bornova, Izmir.
authors.forename: A G
authors.initials: AG
authors.lastname: Ozgen
authors.forename: F
authors.initials: F
authors.lastname: Hamulu
authors.forename: F
authors.initials: F
authors.lastname: Bayraktar
authors.forename: S
authors.initials: S
authors.lastname: Cetínkalp
authors.forename: C
authors.initials: C
authors.lastname: Yilmaz
authors.forename: M
authors.initials: M
authors.lastname: Túzún
authors.forename: T
authors.initials: T
authors.lastname: Kabalak
mesh_terms: D020909:Acarbose / Q000008:administration & dosage* / Q000009:adverse effects; D000328:Adult; D002096:C-Peptide / Q000097:blood; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005951:Glucose Tolerance Test; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007003:Hypoglycemia / Q000097:blood / Q000188:drug therapy*; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged
chemical_list: D002096:C-Peptide; D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D007328:Insulin; D020909:Acarbose